#globalhealthcarecompany — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #globalhealthcarecompany, aggregated by home.social.
-
ESTEVE’S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY
New assets in both businesses – Pharma and CDMO – fuel double-digit growth in net revenues and EBITDA…
#Europe #EU #CDMO #developmentcapabilities #ESTEVE #EuropeanUnion #globalhealthcarecompany #growthstrategy #inorganicgrowth #strategyexecution
https://www.europesays.com/europe/30951/ -
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region https://www.byteseu.com/1454406/ #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #OSAS #Pharma #RegulatoryApproval #StatusEpilepticus #Viatris
-
https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar
-
https://www.alojapan.com/1392924/viatris-completes-acquisition-of-aculys-pharma-including-exclusive-rights-to-pitolisant-in-japan-and-to-spydia-in-japan-and-certain-other-markets-in-the-asia-pacific-region/ Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region #AsiaPacificRegion #ExcessiveDaytimeSleepiness #GlobalHealthcareCompany #InnovativeProducts #Japan #JapanNews #news #OSAS #pharma #RegulatoryApproval #StatusEpilepticus #Viatris Strengthens Viatris’ Presence in Japan With the Addition of Two Innovative Assets Targeting Ar